The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ARGENX SE | SPONSORED ADR | 04016X101 | 8,941,920 | 24,000 | SH | SOLE | 24,000 | 0 | 0 | |||
| ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | 25,869,240 | 1,018,474 | SH | SOLE | 1,018,474 | 0 | 0 | |||
| ARVINAS INC | COM | 04335A105 | 17,182,668 | 628,941 | SH | SOLE | 628,941 | 0 | 0 | |||
| BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 28,021,077 | 622,829 | SH | SOLE | 622,829 | 0 | 0 | |||
| GENMAB A/S | SPONSORED ADS | 372303206 | 9,169,940 | 242,848 | SH | SOLE | 242,848 | 0 | 0 | |||
| INVESCO QQQ TR | UNIT SER 1 | 46090E103 | 70,604,600 | 220,000 | SH | Put | SOLE | 0 | 0 | 220,000 | ||
| KYMERA THERAPEUTICS INC | COM | 501575104 | 17,817,260 | 601,325 | SH | SOLE | 601,325 | 0 | 0 | |||
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 4,443,607 | 4,552,876 | SH | SOLE | 4,552,876 | 0 | 0 | |||
| REGENXBIO INC | COM | 75901B107 | 15,714,475 | 831,014 | SH | SOLE | 831,014 | 0 | 0 | |||
| SILENCE THERAPEUTICS PLC | ADS | 82686Q101 | 8,135,845 | 1,312,233 | SH | SOLE | 1,312,233 | 0 | 0 | |||
| MERUS N V | COM | N5749R100 | 22,542,006 | 1,225,109 | SH | SOLE | 1,225,109 | 0 | 0 | |||
| UNIQURE NV | SHS | N90064101 | 12,839,774 | 637,526 | SH | SOLE | 637,526 | 0 | 0 | |||